With the gradual disclosure of RCTs for CDK4/6 inhibitors in combination with ET in patients with HR+/HER2− breast cancer, an increasing number of MAs and SRs are summarizing and analyzing clinical efficacy from multiple perspectives. The gene discussed is CDK4; the disease is breast carcinoma.